Ovesco Logo

Ovesco Endoscopy AG

Innovation in scope

Ovesco Endoscopy AG is a research-based medical device company operating in the fields of flexible endoscopy and endoluminal surgery.

Ovesco develops, manufactures and markets instruments and systems for the treatment of gastrointestinal diseases. Ovesco offers comprehensive procedures, not only products, and support you all the way from training to intervention.

Ovesco’s hallmark are innovative endoscopic clipping systems. The OTSC® is the product platform for the treatment of gastrointestinal hemorrhage and for endoscopic digestive organ wall closure. Ovesco's clip technology forms a solid basis for many other procedures. Over the years, the portfolio has been expanded by novel resection techniques such as FTRD® and RESECT+, and also diagnostic sensor capsules such as the HemoPill®.

The headquarters is based in Tuebingen, Germany. Furthermore, Ovesco has locations in France and the USA. Patients are treated with Ovesco products in over 70 countries worldwide.

Category Medical technology
Working areas Development, Diagnostics, Artificial intelligence, Medical products, Therapy
Year of foundation
2002
Employees
> 100

News

16.02.2022

HemoPill acute and HemoPill monitor are promising technologies for the detection of blood/hematin in the upper GI tract

Preliminary data of first clinical studies show fast and reliable detection of active bleeding in the upper GI tract and the small intestine by the HemoPill acute. Substantial…

02.02.2022

EMR+: Successful removal of a complex colonic lesion with help of the additional working channel AWC

A case report describes the successful removal of a 22 mm non-granular laterally spreading across-fold lesion in the proximal colon with the EMR+ technique

13.01.2022

OTSC: AGA Clinical Practice Update recommends OTSC and stentfix OTSC

The guideline recommends first-line OTSC therapy for esophageal perforation 1 – 2 cm in size, gastric perforations 1 – 3 cm in size, <13 mm type 1 duodenal perforations and…

27.10.2021

OTSC®: Systematic review confirms 85.2 % clinical success rate and 1 % adverse events in the management of iatrogenic GI perforations

A systematic review of studies evaluating OTSC application for repair of iatrogenic perforations identified 12 studies with overall 191 patients. Pooled proportion analysis…